Call us today for a free and confidential consultation with Paul & Hanley, LLP.  We are one of the nation's leading toxic tort litigation law firms  We'll discuss your specific case and give you honest answers to your important questions.

Our toll-free number is (800) 933-2244.  We look forward to helping you.

To Prevent spam please:
7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Our Office Locations

Northern California
1608 Fourth Street,
Suite 300
Berkeley, CA 94710
Phone: 510-559-9980
Fax: 510-559-9970
Map

Southern California
5716 Corsa Ave,
Suite 203
Westlake Village, CA 91362
Phone: 818-865-2807
Fax: 818-865-0805
Map

811 W. Seventh St.
Suite 206
Los Angeles, CA 90017
Phone: 213-689-3278
Fax: 213-689-4309
Map


Screening Trial for Mesothelioma

Mesothelioma Clinical Trials as of June 2008

There are currently 38 clinical trials listed by the National Cancer Institute's website for mesothelima treatments. There is also a trial for screening former asbestos workers for the disease.  A summary of that trial is listed below.

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Screening trial
Trial is active and accepting patients
Age:  50 to 85
Asbestos Screening Study
Trial ID number:  NCT00188890

Trial Description
Summary

Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma).  Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects.  In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers.  Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure.  We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.

Eligibility Criteria

Inclusion Criteria:  Prior asbestos exposure at least 20 years ago and/or documented pleural plaques (chest x-ray evidence)

Resident of Ontario, Canada

Exclusion Criteria:  Prior cancer (except non-melanotic skin cancer)

Trial Contact Information

Trial Lead Organizations/Sponsors

Toronto Western Hospital

Demetris Patsios, MD  Principal Investigator

Michael Johnston, MD  Principal Investigator

Demetris Patsios, MD  Ph: Tel: (416) 603-5800 Ext.2583
  Email: demetris.patsios@uhn.on.ca

Brenda O'Sullivan  Ph: 416-340-4800 Ext.5686
  Email: Brenda.O'Sullivan@uhn.on.ca

Trial Sites:  Canada Ontario Toronto 

  Princess Margaret Hospital
 
  Demetris Patsios, MD Ph: Tel: (416) 603-5800 Ext.2583
  Email: demetris.patsios@uhn.on.ca
 
  Brenda O'Sullivan, MD Ph: 416-340-4800 Ext.5686
  Email: brenda.o'sullivan@uhn.on.ca
 
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00188890
Information obtained from ClinicalTrials.gov on February 27, 2008

Note:  Information about this trial is from the ClinicalTrials.gov database.